Prevention and treatment of lymphatic metastasis by antilymphangiogenic therapy.

Cancer cells escape a tumor by two primary routes—blood vessels and lymphatic vessels—to establish distant metastases. Thus, it seems reasonable to hypothesize that blocking the growth of new blood vessels (angiogenesis) and lymphatic vessels (lymphangiogenesis) will inhibit hematogenic and lymphogenic metastases, respectively. An impressive array of preclinical studies has demonstrated prevention and suppression of hematogenic metastases by antiangiogenic and antivascular approaches. Whether antilymphangiogenic and antilymphatic approaches will yield similar results for lymphogenic metastases remains to be seen. Both vascular endothelial growth factor

[1]  K. Alitalo,et al.  Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. , 2002, Journal of the National Cancer Institute.

[2]  Rakesh K Jain,et al.  Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics , 2002, Science.

[3]  Peter Carmeliet,et al.  Molecular mechanisms of lymphangiogenesis in health and disease. , 2002, Cancer cell.

[4]  R. Jain,et al.  Intratumoral lymphatic vessels: a case of mistaken identity or malfunction? , 2002, Journal of the National Cancer Institute.

[5]  P. Hewett,et al.  Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. , 2002, Cancer research.

[6]  Adrian L Harris,et al.  Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. , 2002, Cancer research.

[7]  M. Schindl,et al.  Inflammatory stromal reaction correlates with lymphatic microvessel density in early-stage cervival cancer. , 2001, Anticancer research.

[8]  S. Breiteneder-Geleff,et al.  Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. , 2001, Anticancer research.

[9]  K. Sugiyama,et al.  Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. , 2001, European journal of cancer.

[10]  I. Fidler,et al.  Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. , 2001, Surgical oncology clinics of North America.

[11]  Tesshi Yamada,et al.  Expression of vascular endothelial growth factor receptor 3 in blood and lymphatic vessels of lung adenocarcinoma , 2001, The Journal of pathology.

[12]  P. Carmeliet,et al.  Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. , 2001, Cancer research.

[13]  L. Orci,et al.  Vascular endothelial growth factor‐C‐mediated lymphangiogenesis promotes tumour metastasis , 2001, The EMBO journal.

[14]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[15]  Steven A. Stacker,et al.  VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.

[16]  M. Schindl,et al.  Lymphatic microvessel density as a novel prognostic factor in early‐stage invasive cervical cancer , 2001, International journal of cancer.

[17]  M. Schindl,et al.  Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic influence of blood and lymphatic vessel invasion in early-stage cervical cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  S. Fox,et al.  The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  M. Schindl,et al.  Lymphatic microvessel density in epithelial ovarian cancer: its impact on prognosis. , 2000, Anticancer research.

[20]  R. Jain,et al.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.

[21]  Y. Saito,et al.  Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. , 2000, Gynecologic oncology.

[22]  R. Zarbo,et al.  Microvessels that predict axillary lymph node metastases in patients with breast cancer. , 2000, Archives of surgery.

[23]  D. Birnbaum,et al.  Prognosis of breast‐carcinoma lymphagenesis evaluated by immunohistochemical investigation of vascular‐endothelial‐growth‐factor receptor 3 , 2000, International journal of cancer.

[24]  L. Mariani,et al.  Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. , 1999, The American journal of pathology.

[25]  R. K. Bright,et al.  VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours , 1999, British Journal of Cancer.

[26]  K. Kudo,et al.  Relation between lymphatic vessel diameter and clinicopathologic parameters in squamous cell carcinomas of the oral region , 1999, Cancer.

[27]  Takuma Sasaki,et al.  Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  E Yamamoto,et al.  Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. , 1997, Oral oncology.

[29]  U. Weidle,et al.  Lack of lymphangiogenesis in human primary cutaneous melanoma. Consequences for the mechanism of lymphatic dissemination. , 1997, The American journal of pathology.

[30]  B. Achinstein,et al.  Journal of the National Cancer Institute, Vol. 29, 1962: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. , 2009, Nutrition reviews.

[31]  R J DUBOS,et al.  Health and disease. , 1960, JAMA.